Log in

NASDAQ:DYAX - Dyax Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average Volume5.25 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Dyax Corp is a biopharmaceutical company. The Company is focused on Hereditary Angioedema (HAE) and other Plasma-Kallikrein-Mediated (PKM) Disorders, and licensing and funded research portfolio. The Company develops and commercializes treatments for hereditary angioedema. The Company discovered and developed KALBITOR, a plasma kallikrein inhibitor, and is selling it in the United States for the treatment of acute attacks of HAE. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Current SymbolNASDAQ:DYAX
CUSIP26746E10
Phone+1-617-2505769

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive DYAX News and Ratings via Email

Sign-up to receive the latest news and ratings for DYAX and its competitors with MarketBeat's FREE daily newsletter.


Dyax (NASDAQ:DYAX) Frequently Asked Questions

What is Dyax's stock symbol?

Dyax trades on the NASDAQ under the ticker symbol "DYAX."

How were Dyax's earnings last quarter?

Dyax Corp. (NASDAQ:DYAX) announced its earnings results on Wednesday, October, 28th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.08). The biopharmaceutical company had revenue of $24.70 million for the quarter, compared to analyst estimates of $24.96 million. The firm's revenue for the quarter was up 12.3% on a year-over-year basis. During the same period last year, the firm earned ($0.01) earnings per share. View Dyax's Earnings History.

Has Dyax been receiving favorable news coverage?

Media coverage about DYAX stock has trended very negative recently, InfoTrie reports. The research firm identifies positive and negative press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Dyax earned a daily sentiment score of -3.3 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for Dyax.

Who are some of Dyax's key competitors?

What other stocks do shareholders of Dyax own?

What is Dyax's official website?

The official website for Dyax is http://www.dyax.com/.

How can I contact Dyax?

Dyax's mailing address is 55 Network Dr, BURLINGTON, MA 01803-2756, United States. The biopharmaceutical company can be reached via phone at +1-617-2505769.


MarketBeat Community Rating for Dyax (NASDAQ DYAX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  218 (Vote Outperform)
Underperform Votes:  160 (Vote Underperform)
Total Votes:  378
MarketBeat's community ratings are surveys of what our community members think about Dyax and other stocks. Vote "Outperform" if you believe DYAX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DYAX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/23/2020 by MarketBeat.com Staff

Featured Article: VIX - Volatility Index

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel